AKT1 and urinary bladder cancer: As illustrated, lower YTHDC1 expressed cancer cells indicate poor cisplatin outcome in bladder cancer patients; lower YTHDC1 destabilizes PTEN mRNA, thus activates AKT‐associated DNA damage response and attenuates cisplatin‐induced DNA damage.